Statin ineffective for heart patients

Taking rosuvastatin does not reduce the risk of cardiovascular events in heart failure patients, Italian research shows.

For the study, 2,285 patients were assigned to receive rosuvastatin, 10mg daily, while 2,289 patients were given a placebo.

At the end of the three-year study, the researchers found that 29 per cent of patients in the rosuvastatin group died from any cause compared with 28 per cent in the placebo group.

In addition, more patients from the rosuvastatin group - 57 per cent - were admitted to hospital.

In the placebo group, just 56 per cent of patients were admitted to hospital.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus